555
Views
30
CrossRef citations to date
0
Altmetric
Drug Profile

Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism

, &
Pages 343-349 | Published online: 03 Mar 2014
 

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease etiology worldwide. It encompasses a spectrum ranging from simple steatosis to non-alcoholic steatohepatitis. Although the physiopathology of NAFLD is partly known. Insulin-resistance plays a central role in the development and progression of NAFLD. Several studies have indicated that metformin, as an insulin sensitizer, effectively improves NAFLD and its related metabolic status. Metformin was effective in reducing enzyme levels in the short period, but very limited and controversial information are available on liver histology. Larger randomized controlled trials of sufficient duration using clearly defined histological endpoints are needed to fully assess the efficacy of this drug in modifying the natural history of NAFLD.

Acknowledgements

The authors are grateful to SH Price (John F Kennedy Memorial Hospital, Indio, CA, USA) for her assistance in medical literature search.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Key issues

  • Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide.

  • The insulin resistance plays the central role in the development and progression of NAFLD.

  • Metformin could have a beneficial role in the patients with NAFLD, improving liver biochemistry and metabolic syndrome features.

  • Metformin also appears to be safe in mild liver disease.

  • Metformin effect on liver histology remains controversial.

  • Larger randomized controlled trials are needed to fully assess the efficacy of metformin in NAFLD.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 602.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.